99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study
to investigate the diagnostic performance and evaluation efficacy of 99mTc-HPArk2 in breast
cancer patients. A single dose of 11.1Mega-Becquerel (MBq) per kilogram body weight
99mTc-HPArk2 will be injected intravenously. Visual and semiquantitative method will be used
to assess the SPECT/CT images.